FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						
nours per respon	se 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																		
1. Name and Address of Reporting Person * FROST PHILLIP MD ET AL						2. Issuer Name and Ticker or Trading Symbol Opko Health, Inc. [OPK]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
(Last) (First) (Middle) OPKO HEALTH, INC., 4400 BISCAYNE BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 05/10/2017									X Officer (give title below) Other (specify below) CEO & Chairman						
(Street) MIAMI, FL 33137				4. If										6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_Form filed by More than One Reporting Person						
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui							cquir	red, Disposed of, or Beneficially Owned							
1.Title of S (Instr. 3)	(Instr. 3) Date (Month/Day/Year) ar		Executi any	xecution Date, if Code (Inst				ion	on 4. Securities Acquired (A or Disposed of (D) (Instr. 3, 4 and 5)			l (A)	Beneficially Owned Following Reported Transaction(s)			Ownership of Form:	Beneficial			
					(Month	/Day/Ye	ar)	Code	e	V	Amount	(A) or (D)	Pı	rice	(Instr. 3	Instr. 3 and 4) Direct (D) or Indirect (I) (Instr. 4)		Ownership (Instr. 4)		
Common	Stock														3,068,9	951		D		
Common	Stock		05/10/	2017				P			1,125,00	00 A	\$ 6.9 (1)		162,41	11,643		I	See Footnote	
Common	Stock														20,091	,062		I	See Footnote	
Reminder: indirectly.	Report on a	separate lin	e for eac	h class of se	curities	beneficia	ally	owned	l dire	ectly	or or									
Persons who respond to the collection of information SEC 1474 (9 contained in this form are not required to respond unless the form displays a currently valid OMB control number.										EC 1474 (9- 02)										
				Table II ·							Disposed on the conver				y Owned	l				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) any (Month/Dative			Date, if	tte, if Transaction Code Year) (Instr. 8)			of		6. Date Exercisable and Expiration Date (Month/Day/Year)		;	Amou Unde Secur (Instr 4)	le and unt of rlying rities . 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Owners Form of Derivat Securit Direct or India	Ownership y: (Instr. 4) D) ect	
						Code	V	(A)	(D)	Ez	ate xercisable	Expirat Date	tion ,	Title	or Number of Shares					

Reporting Owners

Parada Omas Nasa / Adda	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
FROST PHILLIP MD ET AL OPKO HEALTH, INC. 4400 BISCAYNE BLVD. MIAMI, FL 33137	X	X	CEO & Chairman						
Frost Gamma Investments Trust 4400 BISCAYNE BLVD. MIAMI, FL 33137		X							

Signatures

Phillip Frost, M.D., Individually and as Trustee	05/11/2017	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.66 to \$7.10, inclusive. The reporting person (1) undertakes to provide to OPKO Health, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
 - The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole
- (2) shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- These securities are owned directly by The Frost Group, LLC. Frost Gamma Investments Trust is a principal member of The Frost Group, LLC. The reporting person (3) disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

JOINT FILER INFORMATION

Name: Frost Gamma Investments Trust

Address:

4400 Biscayne Blvd. Miami, FL 33137

Designated Filer: Phillip Frost, M.D.

Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)

Date of Earliest Transaction: May 10, 2017

Relationship to Issuer: 10% Owner

FROST GAMMA INVESTMENTS TRUST

By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee